samedan logo
 
 
spacer
home > pmps > summer 2003 > curing the on-pack information headache
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Curing the On-Pack Information Headache

Legislation relating to on-pack labelling increasingly requires that clear, adequate information is provided to the patient/end-user with key text displayed in the 'local' language (1). More information, including multilingual information, can impact on a number of packaging issues - such as insufficient space for text, high levels of stock materials for each country, more inventory and therefore increased risk of mis-labelling. Curing this headache and adding other benefits has seen the booklet-label become a popular solution across the pharmaceutical industry.

It should be noted that this solution is not exclusive to the pharmaceutical industry. Around the world, diverse organisations utilise the system to provide information, or indeed promotion on equally diverse products. Typically, agrochemical and other chemical products, animal health, cosmetics and toiletries, FMCG and DIY all regularly use booklet-labels. However, the fastest growing market is pharmaceuticals, with clinical trials applications experiencing exponential growth worldwide.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stephen Jarrold, Pharmaceutical & Healthcare Market Manager at Denny Bros Ltd

Stephen Jarrold is Pharmaceutical and Healthcare Market Manager at Denny Bros. In 1983 a temporary packing job lasting two weeks began Stephen's 20 year career with Denny Bros, the Fix-a-Form booklet label inventors. Each time he tried to leave, a new challenge was put to him and so he worked through all departments, finally specialising in marketing and market development where he has been for the past 14 years. Stephen has travelled around the world helping to train and develop the 22 international Fix-a-Form licensees. This role has included speaking at seminars on issues relating to the provision of on-pack information using the multi-page labelling system.

spacer
Stephen Jarrold
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement